Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.830
+0.040 (2.23%)
At close: Dec 20, 2024, 4:00 PM
1.880
+0.050 (2.72%)
After-hours: Dec 20, 2024, 7:03 PM EST
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Akebia Therapeutics stock has a target of 7.50, which predicts an increase of 309.84% from the current stock price of 1.83.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 23, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for AKBA is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +309.84% | Oct 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +309.84% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +309.84% | Oct 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7.5 | Strong Buy | Reiterates | $7.5 | +309.84% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $7.5 | Strong Buy | Maintains | $6 → $7.5 | +309.84% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
157.69M
from 194.62M
Decreased by -18.98%
Revenue Next Year
206.34M
from 157.69M
Increased by 30.85%
EPS This Year
-0.31
from -0.28
EPS Next Year
-0.14
from -0.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 165.0M | 249.0M | 256.3M | |||
| Avg | 157.7M | 206.3M | 249.0M | |||
| Low | 149.1M | 164.1M | 239.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -15.2% | 57.9% | 24.2% | |||
| Avg | -19.0% | 30.9% | 20.7% | |||
| Low | -23.4% | 4.1% | 15.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.27 | 0.08 | 0.44 | |||
| Avg | -0.31 | -0.14 | 0.43 | |||
| Low | -0.34 | -0.34 | 0.41 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.